HER2/Neu GP2 vaccine

Drug Profile

HER2/Neu GP2 vaccine

Alternative Names: GP2 peptide + GM-CSF vaccine; GP2 peptide - Antigen Express; HER2/Neu Peptide GP2; HER2/neu peptide vaccine

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigen Express; Norwell Inc
  • Developer Antigen Express
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 16 Nov 2015 Phase II development is ongoing in USA, Germany and Greece
  • 01 Jan 2007 Phase-II clinical trials in Breast cancer in Germany (Intradermal)
  • 01 Jan 2007 Phase-II clinical trials in Breast cancer in Greece (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top